34P Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET Exon 14 (metex14) Skipping NSCLC

F. Griesinger,M. C. Garassino,E. Felip,H. Sakai,X. Le,R. Veillon,E. F. Smit,J. Raskin, M. Thomas,M-J. Ahn, S. Vlassak,R. Bruns,A. Johne,P. K. Paik

Journal of thoracic oncology（2023）

引用 0|浏览9

暂无评分

摘要

Tepotinib is a MET TKI approved for METex14 skipping NSCLC. We report Tx sequencing prior/post tepotinib of immunotherapy (IO), chemotherapy (CT) and METi (post only) in VISION (data cutoff: Feb 20, 2022).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要